Modality
Vaccine
MOA
C5i
Target
CD38
Pathway
NF-κB
ETGIST
Development Pipeline
Preclinical
Dec 2024
→ Jun 2031
PreclinicalCurrent
NCT05472703
1,511 pts·ET
2025-07→2028-11·Active
NCT03932707
993 pts·GIST
2024-12→2031-06·Completed
2,504 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-11-032.6y awayInterim· ET
2031-06-035.2y awayInterim· GIST
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Complet…
Preclinical
Active
Catalysts
Interim
2028-11-03 · 2.6y away
ET
Interim
2031-06-03 · 5.2y away
GIST
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05472703 | Preclinical | ET | Active | 1511 | DOR |
| NCT03932707 | Preclinical | GIST | Completed | 993 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 |